EpiMedTechGlobal (EMTG) is at the forefront of healthcare innovation, specializing in epigenetics to enhance disease prevention and early detection. Founded in 2016 by renowned scientist Dr. Moshe Szyf, EMTG's mission is to revolutionize healthcare through accessible, cost-effective solutions that empower individuals globally. The brand focuses primarily on cancer care, offering state-of-the-art blood tests that leverage DNA methylation techniques to improve diagnostic accuracy.

In addition to its diagnostic services, EMTG advocates for a healthy lifestyle and ongoing support for epigenetics research, striving to contribute significantly to global health advancements. With a leadership team comprised of accomplished experts, including Chief Innovation Officer Dr. David Cheishvili and Medical Director Dr. Carlos Luiz, EMTG is dedicated to pioneering new tests and technologies. Their commitment to merging science and practical applications showcases their aim to drive healthcare forward, promoting early disease detection and healthier aging for all.